WHAT IS CLAIMED IS:

1. A method of treating a relapsed cancer in a mammal, said method comprising administering to said mammal a pharmaceutical composition comprising a liposome-encapsulated vinca alkaloid.

2. The method of claim 1, wherein said relapsed cancer is a lymphoma or leukemia.

3. The method of claim 1, wherein said relapsed cancer is a non-Hodgkin's Lymphoma.

4. The method of claim 1, wherein said non-Hodgkin's Lymphoma is a member selected from the group consisting of low grade non-Hodgkin's Lymphoma, intermediate grade non-Hodgkin's Lymphoma, follicular lymphoma, large cell lymphoma, B-cell lymphoma, T-cell lymphoma, Mantle cell lymphoma, Burkitt's lymphoma, NK cell lymphoma, and acute lymphoblastic lymphoma.

5. The method of claim 1, wherein said vinca alkaloid is vincristine.

6. The method of claim 1, wherein said vinca alkaloid is selected from the group consisting of vinblastine, vindesine, and vinorelbine.

7. The method of claim 1, wherein said liposome comprises distearoylphosphatidylcholine.

8. The method of claim 7, wherein said liposome further comprises cholesterol.

9. The method of claim 1, wherein said liposome comprises sphingomyelin.

10. The method of claim 9, wherein said liposome further comprises cholesterol.

11. The method of claim 1, wherein said liposome comprises a pH gradient.

12. The method of claim 11, wherein the pH gradient is such that the pH is lower at the interior of said liposome than at the exterior of said liposome.

13. The method of claim 1, wherein said mammal is a human.

14. The method of claim 1, wherein said mammal has previously undergone at least one chemotherapy treatment.

15. The method of claim 14, wherein said at least one chemotherapy treatment comprised administration of a free-form vinca alkaloid.

16. The method of claim 15, wherein said free-form vinca alkaloid is a member selected from the group consisting of vincristine, vinblastine, vindesine, and vinorelbine.

17. The method of claim 14, wherein said at least one chemotherapy treatment comprised administration of an anthracycline-containing combination regimen.

18. The method of claim 17, wherein said anthracycline is doxorubicin.

19. The method of claim 14, wherein said mammal has exhibited a partial response or a complete response to said chemotherapy prior to the relapse of said cancer.

20. The method of claim 19, wherein said relapse is a second relapse.

21. The method of claim 1, wherein said liposome-encapsulated vinca alkaloid is administered systemically by intravenous delivery.

22. The method of claim 1, wherein said liposome-encapsulated vinca alkaloid is co-administered with at least one additional chemotherapeutic agent.

23. The method of claim 22, wherein said at least one additional chemotherapeutic agent is a member selected from the group consisting of cyclophosphamide, doxorubicin, prednisone, and combinations thereof.

24. The method of claim 1, wherein said liposome-encapsulated vinca alkaloid is co-administered with at least one additional anti-tumor agent.

25. The method of claim 24, wherein said additional anti-tumor agent is a monoclonal antibody.

26. The method of claim 25, wherein said monoclonal antibody is a member selected from the group consisting of Rituxan™, Oncolym™, and Bexxar™.

27. The method of claim 24, wherein said additional anti-tumor agent is an antisense drug or an anti-tumor vaccine.

28. The method of claim 5, wherein said vincristine is administered at a dosage of between about 1.4 to about 2.4 mg/m^2 to said patient.

29. The method of claim 5, wherein said vincristine is administered to said patient once every 7-21 days.

30. The method of claim 29, wherein said vincristine is administered to said patient once every 14 days.

31. A method of treating a non-Hodgkin's Lymphoma in a patient, said method comprising administering to the patient a pharmaceutical composition comprising a liposome-encapsulated vinca alkaloid, wherein said composition is free of cardiolipin.

32. The method of claim 31, wherein said vinca alkaloid is vincristine.

33. The method of claim 31, wherein the dosage of said vinca alkaloid is greater than about 1.4 mg/m^2.

34. The method of claim 33, wherein said dosage is between about 1.4 to about 2.4 mg/m^2.

35. The method of claim 33, wherein said composition is administered to said patient once every 7-21 days.

36. The method of claim 35, wherein said composition is administered to said patient once every 14 days.

37. The method of claim 31, wherein said vinca alkaloid is a member selected from the group consisting of vinblastine, vindesine, and vinorelbine.

38. The method of claim 31, wherein said liposome comprises a neutral lipid.

39. The method of claim 31, wherein said liposome comprises distearoylphosphatidylcholine.

40. The method of claim 39, wherein said liposome further comprises cholesterol.

41. The method of claim 31, wherein said liposome comprises sphingomyelin.

42. The method of claim 41, wherein said liposome further comprises cholesterol.

43. The method of claim 31, wherein said liposome comprises a pH gradient.

44. The method of claim 43, wherein the pH gradient is such that the pH is lower at the interior of said liposome than at the exterior of said liposome.

45. The method of claim 31, wherein said non-Hodgkin's Lymphoma is a relapsed non-Hodgkin's Lymphoma.

46. The method of claim 31, wherein said patient has previously undergone at least one chemotherapy treatment.

47. The method of claim 46, wherein said at least one chemotherapy treatment comprised administration of a free-form vinca alkaloid.

48. The method of claim 47, wherein said free-form vinca alkaloid is a member selected from the group consisting of vincristine, vinblastine, vindesine, and vinorelbine.

49. The method of claim 46, wherein said at least one chemotherapy treatment comprised administration of an anthracycline-containing combination regimen.

50. The method of claim 49, wherein said anthracycline is doxorubicin.

51. The method of claim 46, wherein said patient has exhibited a partial response or a complete response to said chemotherapy treatment prior to the relapse of said non-Hodgkin's Lymphoma.

52. The method of claim 31, wherein said liposome-encapsulated vinca alkaloid is administered by systemic delivery.

53. The method of claim 52, wherein said systemic delivery comprises intravenous delivery.

54. The method of claim 31, wherein said liposome-encapsulated vinca alkaloid is co-administered with at least one additional chemotherapeutic agent.

55. The method of claim 54, wherein said at least one additional chemotherapeutic agent is a member selected from the group consisting of cyclophosphamide, doxorubicin, prednisone, and combinations thereof.

56. The method of claim 31, wherein said liposome-encapsulated vinca alkaloid is co-administered with at least one additional anti-tumor agent.

57. The method of claim 56, wherein said additional anti-tumor agent is a monoclonal antibody.

58. The method of claim 57, wherein said monoclonal antibody is a member selected from the group consisting of Rituxan™, Oncolym™, and Bexxar™.

59. The method of claim 56, wherein said additional anti-tumor agent is an antisense drug or anti-tumor vaccine.

60. A method of treating a transformed cancer in a mammal, said method comprising administering to said mammal a pharmaceutical composition comprising a liposome-encapsulated vinca alkaloid.

61. The method of claim 60, wherein said transformed cancer is a non-Hodgkin's Lymphoma.

62. The method of claim 60, wherein said vinca alkaloid is vincristine.

63. The method of claim 60, wherein said liposome comprises sphingomyelin and cholesterol.

64. A method to treat a neoplasia in a mammal, said method comprising administering to said mammal a liposome-encapsulated vinca alkaloid in a dosage of from about 1.4 to about 2.4 mg/m^2.

65. The method of claim 64, wherein said vinca alkaloid is administered to said mammal once every 7-21 days.

66. The method of claim 65, wherein said vinca alkaloid is administered to said mammal once every 14 days.

67. The method of claim 64, wherein said vinca alkaloid is co-administered to said mammal with a prophylactic or therapeutic treatment for neurotoxicity.

68. A kit for use in the treatment of a neoplasia in a mammal, said kit comprising components useful in the preparation of a liposome-encapsulated vinca alkaloid, instructions for preparing the liposome-encapsulated vinca alkaloids, and instructions for the use of the liposome-encapsulated vinca alkaloids in the treatment of said neoplasia.

69. The kit of claim 68, wherein said kit comprises at least three vials, wherein one of the vials contains vincristine sulfate, a mannitol buffer, and sodium acetate, wherein one of the vials contains liposomes comprising sphingomyelin and cholesterol suspended in a citrate buffer, and wherein one of the vials contains an alkaline phosphate buffer.

70. A kit for use in the treatment of a neoplasia in a mammal, said kit comprising a stable formulation of liposome-encapsulated vinca alkaloids and instructions for the use of the liposome-encapsulated vinca alkaloids in the treatment of said neoplasia.